Riskpilot← Back to searchSign inGet full accessPharma Components ApS
APSActiveCVR 39103079Arnegårds Alle 12Wholesale of other machinery and equipment · NACE 4664Est. 2017— employeeswww.pharmacomponents.dk
Revenue 2024
DKK 336K
+45% vs 2023
EBITDA margin
100.0%
+45% vs 2023
Equity ratio
48.1%
Financial strength
Net profit 2024
DKK 142K
-28% vs 2023
| Revenue | DKK 336K | +45% |
| EBITDA | DKK 336K | +45% |
| Net profit | DKK 142K | -28% |
| Total assets | DKK 805K | +28% |
| Equity | DKK 388K | +58% |
| Employees | — | — |
Legal name
Pharma Components ApS
CVR number
39103079
Legal form
Anpartsselskab
NACE code
4664 · Wholesale of other machinery and equipment
Founded
21. november 2017
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør alene
Company purpose
Selskabets formål er at drive virksomhed med komponenter til fødevare og medicinal industrien og hermed forbundet virksomhed.
Address
Arnegårds Alle 12
Phone
+4527261622
Email
anders.rieltec@gmail.com
Website
www.pharmacomponents.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 30 | 45 | -17 | -22 | 69 | 232 | 336 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -6 | 45 | -17 | -22 | 69 | 232 | 336 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -6 | 45 | -17 | -22 | 69 | 232 | 336 |
| Net financials | 0 | 0 | 2 | -1 | -4 | 21 | -153 |
| Profit before tax | -6 | 45 | -15 | -23 | 64 | 253 | 183 |
| Tax | -0 | 10 | -0 | -0 | 7 | 57 | 41 |
| Net profit | -6 | 35 | -15 | -23 | 57 | 196 | 142 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 1 | 94 | 81 | 59 | 127 | 627 | 805 |
| Equity | 0 | 31 | 15 | -8 | 49 | 246 | 388 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 | 64 | 66 | 67 | 78 | 381 | 418 |
| Total debt | 1 | 64 | 66 | 67 | 78 | 381 | 418 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20182024
Equity ratio
48.1%
This company
38.2%
Market median
+26% vs market
20182024
Return on equity
36.7%
This company
18.4%
Market median
+99% vs market
20182024
Net profit margin
42.2%
This company
8.1%
Market median
+421% vs market
20182024
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
20182024
Debt / equity
1.08×
This company
0.62×
Market median
-74% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2017-11-21 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PL Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
A.Rocket Holding ApS | Company | 100.0% | 100.0% | 2023 |
Criel Holding ApS | Company | 33.3% | 33.3% | 2019 |
| Individual | 33.3% | 33.3% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
A.Rocket Holding ApS
Pharma Components ApS Board members of Pharma Components ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patrick Lund Ossian | Chief Executive Officer | 0 companies |
| Anders Fossing Riel | Chairman | 0 companies |